A randomized trial for adults with newly diagnosed acute lymphoblastic leukaemia.

Trial Profile

A randomized trial for adults with newly diagnosed acute lymphoblastic leukaemia.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Palifermin (Primary) ; Pegaspargase (Primary) ; Nelarabine; Rituximab
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms UKALL-14
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Jan 2017 Status changed from recruiting to completed.
    • 11 Feb 2016 Accrual to date is 83% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top